Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic clinical trials, observational studies, and health surveys. In the context of RWE, patient recruitment plays a significant role, as the data collected from these individuals helps in understanding the effectiveness, safety, and usage of medical products in the real world.
Traditional Patient Recruitment: In traditional methods, patient recruitment generally happens through methods like physician referrals, media advertising, patient registries, and patient advocacy groups. This method can be time-consuming, costly, and sometimes inefficient, as it often relies on manual efforts. It can also be challenging to find patients who fit specific inclusion and exclusion criteria for a particular study.
AI-Enabled Recruitment: Artificial intelligence (AI) has started transforming patient recruitment in many ways. AI can analyze vast amounts of real-world data from electronic health records (EHRs), medical claims, health surveys, and other digital health platforms to identify eligible patients rapidly. This approach reduces the recruitment timeline and the costs associated with patient enrollment.
AI algorithms can predict the likelihood of patients participating in the study, improving the precision of recruitment. They can also monitor and analyze patient behavior, enabling the refinement of recruitment strategies in real-time. AI can further enhance the diversity of recruited patients by considering a wide range of demographic and geographic factors, leading to a more inclusive and representative study.
AI-enabled recruitment can also help in mitigating potential biases in patient selection by utilizing a data-driven approach. By analyzing historical clinical trial data, AI models can identify patterns and biases in previous studies and correct them in future ones. Furthermore, AI can help in patient retention by predicting the potential drop-out risks and enabling timely intervention.
In conclusion, while traditional methods are essential and remain relevant in certain contexts, AI-enabled recruitment offers the possibility of increased speed, reduced costs, and improved diversity and representativeness of patients in studies generating real-world evidence.
Share this story...
Real World Evidence (RWE) 101 – NICE Real World Evidence Framework
RWE 101 - NICE Real World Evidence Framework The UK's National Institute for Health and Care Excellence (NICE) has developed a Real World Evidence (RWE) Framework to help evaluate [...]
Real World Evidence (RWE) 101 – The Role of RWE in Health Technology Assessments (HTAs)
RWE 101 - The Role of RWE in Health Technology Assessments (HTAs) Real-world evidence (RWE) is becoming increasingly important in the context of health technology assessment (HTA), which is [...]
Real World Evidence (RWE) 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)
RWE 101 - Verifying the Source of Data (Not to be Confused with Source Data Verification...Yup! Confusing!) Verifying the source of data is critical in the context of real [...]
Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)
RWE 101 - Challenges in RWE Generation (Regulatory Grade RWE?) Real-world evidence (RWE) refers to data derived from real-world sources such as electronic health records, claims data, and patient-generated [...]
Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations
RWE 101 - Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations Real-world evidence (RWE) studies include observational studies that uses data collected in real-world settings to [...]
Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies
RWE 101 - Acknowledgement of the Limitations of Clinical Trials and RWE Studies Clinical trials are experiments designed to test the safety and efficacy of new treatments or [...]







